Background. Peritonitis-free survival is commonly reported in the peritoneal dialysis (PD) literature. The Kaplan-Meier method appears to be the only technique used to date, although it has known limitations for cohorts with multiple outcomes, as in PD. In the presence of these 'competing risks' outcomes, the Kaplan-Meier estimate is interpretable only under restrictive assumptions. In contrast, methods which take competing risks into account provide unbiased estimates of probabilities of outcomes as actually experienced by patients. Methods. We analysed peritonitis-free survival in a cohort of 8711 incident patients from the 'Registre de Dialyse Péri-tonéale de Langue Française' between 1 January 2000 and 31 December 2007 by calculating the cumulative incidence (CI) of the first episode of peritonitis using the Kaplan-Meier method and a method accounting for competing risks. We compared the CI in different patient groups by the log-rank test and a test developed for competing risk data, Gray's test. Results. After 5 years of PD, the CI of at least one peritonitis episode was 0.4, and the probability of any outcome was 0.96. The Kaplan-Meier method overestimated the CI by a large amount. Compared with the log-rank test, Gray's test led to different conclusions in three out of seven comparisons. Conclusions. The competing risk approach shows that the CI of at least one peritonitis episode was lower than reported by the Kaplan-Meier method but that survival peritonitis-free and still on PD was overall low. The competing risk approach provides estimates which have a clearer interpretation than Kaplan-Meier methods and could be more widely used in PD research.
Introduction
Patients on dialysis face multiple possible outcomes. For example, peritoneal dialysis (PD) patients can die, be transferred to haemodialysis, or undergo renal transplantation and can also experience less common outcomes, such as partial recovery of renal function. Researchers are frequently interested in the probability of patient survival free of one of these outcomes, or conversely, in the probability of having experienced the outcome at different follow-up times. This latter probability is known as the cumulative incidence (CI).
The common practice in the dialysis literature is to estimate the CI by the Kaplan-Meier (KM) method. Here, one outcome is taken as the event of interest, and patients experiencing the other outcomes, along with patients lost to follow-up, are censored [1] . The CI is then calculated or inferred by the reader as simply one minus the KM survival probability. For example, in peritonitis-free survival analyses, the outcome of interest is the first episode of peritonitis. Patients with the outcomes of death, transfer to haemodialysis or renal transplantation before peritonitis are censored. If the KM method gave a peritonitis-free survival probability of 0.3 at 2 years after starting PD, the CI of first episode of peritonitis at 2 years would be 0.7 by this method.
However, the KM method was developed for situations with only one outcome. It is not adapted to multiple, 'competing risk' outcomes when the occurrence of one outcome changes the probability of the others [2, 3] . In fact, the KM method assumes that the outcomes are independent, or put another way, that it is possible to remove the competing risks without changing the probability of the outcome of interest [4] . This is very unlikely in medical data. In PD, for example, patients transferred to haemodialysis almost certainly do not have the same probability of peritonitis as those who remain on PD. KM estimates in the presence of competing risks can therefore be misleading since they estimate a purely hypothetical quantity without a clear statistical meaning [2, 4] .
Methods to address competing risks have been developed over the last 20 years [2, 5] and are now widely used in other areas of medicine [6] [7] [8] [9] [10] [11] . These methods give unbiased estimates of the CI for each possible outcome as actually experienced by patients without assumptions about the interdependence of the outcomes. They also provide alternatives to the log-rank test, such as Gray's test, for comparing patient groups in the presence of competing risks [12, 13] . Although we will see that these methods also cannot predict the CI of an outcome if the competing risks were somehow removed, they do provide CI estimates which have a clear interpretation [4] . This is why they are recommended by the methodological articles which examine this question [2] [3] [4] [14] [15] [16] [17] .
Although articles applying these methods have started to appear in the renal literature [18] [19] [20] [21] [22] , to the authors' knowledge, there are no estimates of peritonitis-free survival which take competing risks into account. Updating peritonitis-free survival is important since peritonitis is a core indicator in monitoring PD quality: it is a criterion in the KDOQI guidelines [23, 24] and is routinely used to compare PD modalities and systems [25] . The aim of this article is therefore to estimate the CI of the outcome of first episode of peritonitis taking the other outcomes into account as competing risks. Using a large cohort from the 'Registre de Dialyse Péritonéale de Langue Française' (RDPLF), we compare the competing risk and KM CIs and test for differences between patient groups using the log-rank and Gray's tests. We discuss why differences occur and highlight the limitations of both methods. We focus on concepts without mathematical formulae; readers are referred elsewhere for excellent, formal discussions [2, 3, 5] .
Subjects and methods

Data source
Data were from the RDPLF, which was established in 1986 and currently includes 82% of all PD patients in France. Participating centres update patient information every 3 months. Details about registry management have been published elsewhere [26] .
Population
We extracted all adult patients (16 years or older at PD initiation) who started PD between 1 January 2000 and 31 December 2007 in any French hospital participating in the RDPLF, excluding the French overseas territories. The end of the study period was 31 December 2008. We excluded patients with missing data for diabetic status (n = 15) or previous transplantation (n = 43) and those whose outcome was incorrectly coded (n = 23).
Definition of outcomes and other variables
Patient outcome was defined as the earliest event among first episode of peritonitis, death, transfer to haemodialysis, renal transplantation and interruption of PD because of partial recovery of renal function. Patients without any of these outcomes were censored at the date of their last recorded visit or at the end of the study period. The duration between starting PD and patient outcome or censoring was calculated. The following demographic and clinical data were extracted: sex, age at PD initiation, underlying nephropathy (recorded as polycystic kidney disease and other nephropathies), prior renal transplantation, type of PD and type of assistance 90 days after PD initiation, and diabetic status at last visit. We included type of assistance as we have previously reported an association with peritonitis risk. Unlike other countries, nurse-assisted PD is common in France [27] .
Competing risks survival analysis
The event of interest was first episode of peritonitis, and so, the competing risk events were death, transfer to haemodialysis, transplantation and partial recovery of renal function before first peritonitis episode.
We calculated the CI function for each of these outcome events using the approach of Kalbfleisch and Prentice [28] .
Kaplan-Meier survival analysis
We calculated KM product limit probabilities for survival until the first episode of peritonitis, censoring patients experiencing all other outcomes at the date of these outcomes. We calculated KM CIs by subtracting the KM survival probabilities from one. We also calculated the KM CI for a composite outcome combining all five possible outcomes, meaning that only patients lost to follow-up or under follow-up at study end were censored for this specific analysis.
Consistent with recommendations [29] , the duration presented on the CI curves is 36 months since only 10% of the patients were still under follow-up at this time.
Significance testing of survival differences
We tested the statistical significance of differences in the CI of the first episode of peritonitis between selected patient groups using the log-rank test and Gray's test for subdistribution hazards. Statistical significance was accepted at P ≤ 0.05. Patient characteristics compared were sex, age group, diabetic status, underlying polycystic renal disease (data missing for 230 patients), prior transplantation, type of PD at Day 90 after PD initiation and type of assistance at Day 90 after PD initiation (data missing for 268 patients). Nine hundred and ten patients had fewer than 90 days PD and so were excluded from the last two analyses.
Software
Statistical analyses were done with R 2.8.1 [30] , including the survival and cmprsk libraries.
Results
The study involved 8559 patients from 137 hospitals. Patient characteristics are summarized in Table 1 . Patients were mostly elderly but covered a wide age range, with just over one-half male. Continuous ambulatory peritoneal dialysis (CAPD) was the commonest PD modality at Day 90 after starting PD, and most patients were either autonomous in managing their PD or were assisted by a nurse at this time. Diabetes was a common comorbidity, but both underlying polycystic kidney disease and previous renal transplantation were rare (Table 1) .
Follow-up time and outcomes
The median follow-up period was 11.5 months [interquartile range (IQR) 4.5-22.1] with ∼10% of patients (n = 820) still under follow-up at 36 months. The commonest outcome was first peritonitis episode (n = 3137, 36.7%), followed by death before any peritonitis episode (n = 2243, 26.2%). Similar proportions of patients were transferred to haemodialysis (n = 1090, 12.7%) or transplanted (n = 992, 11.6%) before any peritonitis episode. The number of patients with partial recovery of renal function was very small (n = 108, 1.3%). Few patients were censored as lost to follow-up (n = 71, 0.8%) or at the end of the study period (n = 918, 10.7%).
Cumulative incidence of first peritonitis episode Table 2 shows the CI estimates using the competing risks and KM methods. When CI was calculated using the KM method, the probability of experiencing a first peritonitis episode was just over 25% at 1 year of starting PD but reached 70% at 5 years of PD. With competing risks taken into account, the probability of experiencing a first episode of peritonitis at 1 year after starting PD was just under 25% and reached 40% at 5 years after PD initiation.
These results are presented graphically in Figure 1 . Except for the period immediately after starting PD, the KM CI estimates for first episode of peritonitis were always higher than the estimates taking competing risks into account. The difference between the two curves increased with time, as shown by the steeper KM curve.
Cumulative incidence estimates of the other outcomes
The competing risks analysis also allows the calculation of the CI of the other possible outcomes, summarized in Table 2 and shown in Figure 2 . Death before any peritonitis episode was the second-ranked outcome (CI of 0.29 at 60 months), followed by transfer to haemodialysis (0.14) and renal transplantation (0.13) before peritonitis. Partial recovery of renal function was rare (0.01) and stable from soon after PD initiation.
Cumulative incidence of all outcomes combined
The CI curve for the composite event of all five outcomes combined is shown in Figure 2 , and the CIs at different follow-up times are presented in Table 2 . These show that almost all patients experience one of the outcomes at 60-month follow-up (0.96) and that the probability of experiencing one of the possible outcomes was already high (0.86) at 36 months after PD initiation.
Testing for differences in cumulative incidence between patient groups
The statistical significance of differences in peritonitis-free survival for selected patient groups is presented in Table 3 . Gray's test showed statistically significant differences for age group, type of PD and previous transplantation whereas the log-rank test showed statistically significant differences for sex, underlying polycystic kidney disease, previous transplantation and type of PD. The tests therefore gave different conclusions about statistical significance for three of the seven groups examined.
Discussion
This is, to the authors' knowledge, the first analysis of peritonitis-free survival taking competing risks into account. The results suggest that peritonitis-free survival is both 'better' and 'worse' than results obtained with the KM method used to date in the PD literature. Survival is 'better' in the sense that the CI of first episode of peritonitis is smaller than the KM estimates suggest: the competing risks CI was 0.36 after 3 years and 0.39 after 5 years, lower than the corresponding KM estimates of 0.54 and 0.71. However, peritonitis-free survival is also 'worse' in the sense that patients rapidly experienced one of the five possible outcomes, meaning that few patients were peritonitis-free and still on PD at the end of followup. In fact, the probability of being peritonitis free and still on PD was only 0.14 at 3 years and 0.04 at 5 years after starting treatment. Competing risks in peritonitis-free survival Table 2 . For clarity, confidence intervals are not included. Fig. 2 . Cumulative incidence curves for each of the possible outcomes facing peritoneal dialysis patients and for all outcomes combined into a single event. The CI curves for the separate outcomes were calculated by taking competing risks into account and the curve for all outcomes combined by the Kaplan-Meier method. Thirty-six months of follow-up are shown as only 10% of patients were still active at this time. Number of patients still under follow-up at each time point shown in Table 2 . For clarity, confidence intervals are not included.
It may be surprising that two methods applied to the same data can give such different estimates of the CI. This is, however, well described in the survival literature which shows that the divergence between the competing risk and the KM methods increases as the 'strength' of the competing risks increases [2] . Technically, this strength is reflected by the hazard (or the momentary probability of the outcome among patients who have survived until that moment) [3] , but we can refer to incidences to explain this point. As shown in Figure 2 , the CI of the competing risk outcomes, in particular of death, accumulated rapidly in our study, thereby contributing to the large difference between the competing risk and the KM estimates of the CI of first-episode peritonitis.
Of course, the key question is which estimate is the more accurate. In general, our goal is to describe the probability of the outcome of interest, or of all the possible outcomes, actually experienced by patients at different follow-up times. For this goal, competing risks methods give unbiased estimates [2] . The competing risks results in Table 2 show the probability that a patient starting PD experiences each outcome at each follow-up time. In contrast, the KM CI estimate does not correctly estimate these probabilities, for the reasons described below, except when there is only one possible outcome, when the two methods become identical.
However, another research goal may be to estimate the impact on the CI of the outcome of interest if we could hypothetically intervene to remove the other outcomes. Unfortunately, neither the competing risks nor KM methods can answer this question, although we will see that the competing risks approach has an important advantage. There are two main difficulties in answering this from observational data. The first is that outcomes in medicine are usually dependent, so that intervening to remove one outcome will change the others. We can imagine intervening passively in our study to remove a competing risk, say by stopping transfer of PD patients to haemodialysis. In this case, the CI of peritonitis may increase since patients who would have been transferred to haemodialysis may have a higher, but unobserved, peritonitis risk than other patients. However, it is usually impossible to estimate how the peritonitis CI would change in this situation since we usually cannot estimate the dependence between these outcomes from the data.
The second difficulty in responding to this question is that we do not know the impact on the outcome of interest of any active intervention to remove the competing risks. Imagine an intervention, such as a new and unusually effective medical treatment, which delays death. Such a treatment may also lead to a reduction in peritonitis risk through immune stimulation or a similar mechanism. In this case, removing the competing risk of death may in fact entail a reduction in the peritonitis CI. However, such a drug could also increase the peritonitis CI, say by causing constipation and so increasing peritonitis risk amongst patients with diverticular disease. In short, the effect of removing a competing risk is not 'knowable' from the data and may, in fact, be different for different means of removal [4] . Some experts have therefore argued that we cannot begin to address the question of what the CI of an outcome would be if competing risks were removed until the intervention for doing so is clearly specified [16] .
Although neither the competing risk nor the KM methods can adequately address this second goal [4] , the competing risk approach has the advantage of correctly estimating known quantities. This at least provides an unbiased starting point for discussion about how the CI may change if competing risks were made to disappear under different intervention scenarios. In contrast, the KM method yields a poorly defined quantity, making its interpretation difficult. In fact, it is only in the unusual situation of independent outcomes that the KM estimate has a clear meaning, as it can then be used to extract the CI for an outcome under an imagined situation where the other outcomes simply do not exist [2, 3, 31] . This argument has been used to support KM analyses of biomedical prostheses, such as cardiac valves, to extract a 'latent' lifespan [32] . However, the idea is controversial precisely because of the need to assume independent outcomes [3, 15] . As others have pointed out, this may be reasonable in industrial studies where machinery components are physically and functionally separate but would rarely be reasonable in medicine [16] .
In fact, the reason the KM method gives biased CI estimates in the presence of competing risks is that the core assumption of non-informative censoring does not hold [3] . This assumption asserts that censored patients have the same probability of experiencing the event of interest after censoring as patients who remain under follow-up [1] . This is clearly not the case in our study: it would be absurd to pretend that patients who die, undergo transplantation or are transferred to haemodialysis would have the same probability of peritonitis following these outcomes as patients who are lost to follow-up or censored at the study's end.
The difference between the methods lies in how patients experiencing a competing risk event are handled. Simplistically, the incidence of peritonitis on any day is the product of (i) the probability that a patient has reached the beginning of the day peritonitis-free but at-risk and (ii) the probability that a patient has peritonitis on that day. The CI is the sum of these daily incidences. The methods differ in how patients experiencing a competing outcome contribute to the first of these probabilities. In the KM method, these patients are censored, saying statistically that the competing event tells us nothing about the probability of reaching the next day at risk of peritonitis. In contrast, the competing risk method removes these patients from the 'pool' starting the next day, recognizing that they can no longer experience peritonitis on PD [5, 17] . The KM meth- Competing risks in peritonitis-free survivalod therefore overestimates the probability of starting any day at-risk and so overestimates the CI, as seen in Figure 1 . There is, however, a correspondence between the KM and competing risk approaches [3, 17] . The KM method can be used to estimate the CI of a composite outcome of 'any' of the possible events since the only censored patients in this analysis are those truly lost to follow-up or event-free at study end. As shown in Figure 2 , the competing risk CIs for each possible outcome sum to equal the CI for this composite outcome [13, 17] . The competing risks method can also be used to estimate the CI of this composite outcome as it is equivalent to the KM method when only one outcome is possible [17] .
A common question in PD research is whether the CI of a particular outcome differs between patient groups. Because of the competing risks' effects on the CI of the outcome of interest, failing to account for them in such comparisons can lead to erroneous conclusions. For example, the CI of first-episode peritonitis could differ between automated PD (APD) and CAPD groups if older patients were placed on CAPD simply because older patients die more. The single CI estimate provided by the KM method risks masking the effect of different death rates on the peritonitis CI. In contrast, CI estimates taking competing risks into account would show the higher CI of death in the CAPD group, helping flag this as a potential concern.
A similar warning relates to the choice of statistical test used to compare patient groups in the presence of competing risk. The log-rank test and Gray's test can give different results, as in this study, because they compare different statistics. Using peritonitis-free survival as an example, the log-rank test compares the hazards (related to our 'daily' probability above) [33] for peritonitis between groups whilst Gray's test takes the hazards of both peritonitis and the competing outcomes into account [13, 34] . Gray's test is more widely used when comparing competing risk CIs but both tests (and others) are theoretically valid and are reported in the literature [2, 35] . As an area of ongoing research, some authors recommend using both tests to guide conclusions [2, 31, 34] .
The empirical results of our study need to be interpreted in light of the strengths and weaknesses of our data. Obviously, we consider the use of a competing risks method to be a methodological strength. Other strengths are statistical power owing to the large sample size and 8-year study period, and a patient sample representative of PD patients in France owing to the high coverage of the RDPLF [26, 36] . As with all survival analyses, a weakness is possible informative censoring if patients were not randomly lost to follow-up, although this concern would also apply to analysing our data solely by the KM method [1] .
We should also point out that there may be better analytical approaches to handling peritonitis data. We have addressed peritonitis-free survival because it is common in PD research, and there are established methods for competing risks in survival analyses. However, there is a loss of information in any survival analysis approach since peritonitis episodes occurring after the first are, by definition, excluded. Alternative approaches include Poisson models [37] and multi-state models [3, 40] , but these are more data-demanding and can be complex to programme. An advantage of Poisson models is that they use all peritonitis episodes, provide the number of peritonitis episodes per patientmonth familiar to clinicians and can also be adapted to account for clustered data [38, 39] . However, they are still complicated by the need to account for the competing outcomes [41] . This is an area of ongoing research [42] .
Uptake of competing risk survival analyses in renal research has been relatively slow, despite use in oncology, haematology and cardiovascular medicine [6] [7] [8] [9] [10] [11] . Even the orthopaedics literature has identified the need to account for competing risks in technique survival [14] . Competing risks have recently started to appear in the renal literature, for example in patient and technique survival in PD [18] ; cardiac death [21, 22] , cerebrovascular disease [43] and infectious mortality in dialysis [20] ; and end-stage renal disease and non-renal mortality in chronic kidney disease [19] . With competing risk methods now available in standard statistical software (SAS, STATA, R), they may become more widely used in renal research [44] . They may be of interest for re-analyses of studies to assess robustness of conclusions and when designing new projects.
